T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapyGuido Ghilardi, Marco Ruella, Gabriel C. Caponetti et al.|Nature Medicine|2024Cited by 254
Medical management update: Multiple myelomaEric T. Stoopler, Edward A. Stadtmauer, Dan T. Vogl|Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontology|2007Cited by 45
Interim analysis of LimiTec, a prospective trial of limited-duration teclistamab for relapsed/refractory multiple myelomaBeatrice M. Razzo, Alfred L. Garfall, Rajshekhar Chakraborty et al.|Blood|2025Cited by 6